View Exam | PowerPak

1. Which of the following statements regarding hATTR amyloidosis is FALSE?

A. hATTR amyloidosis is inherited in an autosomal dominant fashion B. Cardiac manifestations and neurologic manifestations of hATTR are almost always mutually exclusive C. Autonomic impairment occurs more commonly in hATTR amyloidosis compared with amyloid A amyloidosis or amyloid light chain amyloidosis D. The median survival of patients with hATTR amyloidosis with cardiac involvement is 3.5 years

2. Which of the following treatments is approved as an intravenous infusion therapy for the treatment of hATTR polyneuropathy?

A. Diflunisal B. Inotersen C. Patisiran D. Tafamidis

3. JB is a 57-year-old woman who presents to the community pharmacy to fill an antibiotic prescription for a urinary tract infection. She asks about diarrhea as a side effect, expressing concern because she has a history of self-assessed severe diarrhea. Upon further counseling, she reveals additional symptoms, including that she often feels light-headed when she gets up from her desk at work. You consider the potential for her symptoms to be the result of hATTR amyloidosis. Which of the following symptoms is LEAST LIKELY to confirm your suspicions?

A. Carpal tunnel syndrome B. Tingling sensations in her feet and/or hands C. History of hair loss D. Trouble breathing

4. All the following represent findings of the APOLLO study, EXCEPT:

A. Compared with placebo, patisiran was associated with decreases in adverse cardiac outcomes at 18 months B. Benefits of patisiran were stratified according to specific mutation C. Peripheral edema occurred in approximately one-third of patisiran-treated patients D. Patisiran was associated with improvements in both modified Neuropathy Impairment Score +7 (mNIS+7) scores and Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) scores

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding hATTR amyloidosis is FALSE?

2. Which of the following treatments is approved as an intravenous infusion therapy for the treatment of hATTR polyneuropathy?

4. All the following represent findings of the APOLLO study, EXCEPT:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding hATTR amyloidosis is FALSE?

2. Which of the following treatments is approved as an intravenous infusion therapy for the treatment of hATTR polyneuropathy?

4. All the following represent findings of the APOLLO study, EXCEPT:

« Return to Activity

Customers who Purchased
this Activity also Purchased